Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Fineline Cube May 18, 2026
Policy / Regulatory

CDE Launches Trial Procedures for Adding Pediatric Information to Drug Inserts

Fineline Cube Jul 6, 2023

The Center for Drug Evaluation (CDE) has released the “Work Procedures for Adding Children’s Drug...

Company Deals

Sino Biopharmaceutical’s F-star Therapeutics Inks Third Licensing Deal with Takeda for Immunotherapies

Fineline Cube Jul 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star...

Company Drug

3SBio Inc. Receives NMPA Approval for Nalfurafine Tablets to Treat Hemodialysis-Related Pruritus

Fineline Cube Jul 6, 2023

China-based 3SBio Inc. (HKG: 1530) has announced receiving marketing approval from the National Medical Products...

Company Deals

Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements

Fineline Cube Jul 6, 2023

China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Esflurbiprofen Patch Clinical Study

Fineline Cube Jul 6, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development

Fineline Cube Jul 6, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with...

Company Deals

Nanjing Kati Medical and Leman Biotech Partner to Advance Immune Metabolism Reprogramming in CAR-T Therapy

Fineline Cube Jul 6, 2023

Nanjing Kati Medical Technology Co., Ltd, a China-based company, has entered into a partnership with...

Company Deals

Brii Biosciences Expands Collaboration with VBI Vaccines on Hepatitis B Virus Therapies

Fineline Cube Jul 6, 2023

China-based Brii Biosciences Ltd (HKG: 2137) has announced an expanded license agreement with US firm...

Policy / Regulatory

NMPA Launches “Drug Standard Management Measures” to Enhance Drug Quality and Safety

Fineline Cube Jul 6, 2023

The National Medical Products Administration (NMPA) has released the “Drug Standard Management Measures,” a set...

Company Policy / Regulatory

China’s MofCOM Hosts Symposium with Multinational Corporations, Promises Development Opportunities

Fineline Cube Jul 6, 2023

This week, China’s Ministry of Commerce (MofCOM) convened a symposium attended by representatives from a...

Company Legal / IP

Genprex Inc. Receives Chinese Patent Protection for Reqorsa Immunogene Therapy

Fineline Cube Jul 6, 2023

Texas-based gene therapy company Genprex Inc., (NASDAQ: GNPX), has reported receiving a patent protection award...

Company

Moderna Inc. Plans USD 1 Billion Investment in Shanghai for mRNA Vaccine Production

Fineline Cube Jul 6, 2023

US-based mRNA specialist Moderna Inc. (NASDAQ: MRNA) has revealed further details of its entry into...

Company Drug

CSPC Pharmaceutical Group Receives Marketing Approval for Desvenlafaxine in China

Fineline Cube Jul 6, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving marketing approval in China for...

Company Drug

AbbVie’s Rinvoq Receives NMPA Approval for Moderate to Severe Crohn’s Disease Treatment

Fineline Cube Jul 6, 2023

US pharmaceutical firm AbbVie (NYSE: ABBV) has announced receiving market approval from the National Medical...

Company Drug

Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment

Fineline Cube Jul 5, 2023

Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...

Policy / Regulatory

CDE Releases 72nd Batch of Generic Reference Preparations with New Specifications

Fineline Cube Jul 5, 2023

The Center for Drug Evaluation (CDE) has released the 72nd batch of chemical generic reference...

Company Drug

Huadong Medicine’s Liraglutide Biosimilar Gains NMPA Approval for Weight Loss Indication

Fineline Cube Jul 5, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received additional indication...

Company Drug

Abbisko Therapeutics’ EGFR Inhibitor ABSK112 Clears FDA for Global Phase I NSCLC Study

Fineline Cube Jul 5, 2023

Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...

Company Drug

Jacobio Pharma’s KRAS Inhibitor Glecirasib Advances to Pivotal Pancreatic Cancer Trial

Fineline Cube Jul 5, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that it has received the green light from...

Company Drug

InnoCare Pharma Initiates Clinical Trial for TYK2 Inhibitor ICP-488 in Psoriasis Patients

Fineline Cube Jul 5, 2023

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced a significant milestone in the clinical...

Posts pagination

1 … 507 508 509 … 667

Recent updates

  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.